With effect from April 08, 2024, the unit rights in Diagonal Bio AB will be traded on First North Growth Market. Trading will continue up until and including April 17, 2024. Instrument: Unit rights Short name: DIABIO UR Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0021921566 Order book ID: 330834 Market Segment: First North STO Tick Size: MiFID II tick size table With effect from April 08, 2024, the paid subscription units in Diagonal Bio AB will be traded on First North Growth Market. Trading will continue until and including May 10, 2024. Instrument: Paid subscription units Short name: DIABIO BTU Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0021921574 Order book ID: 330833 Market Segment: First North STO Tick Size: MiFID II tick size table For further information concerning this exchange notice please contact Issuer Surveillance, telephone +46 8 405 70 50, or iss@nasdaq.com Nasdaq Stockholm AB
Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Diagonal Bio AB
© 2024 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.04. | Nasdaq Stockholm AB: The observation status for Diagonal Bio AB is removed | On February 5, 2024, the shares in Diagonal Bio AB (the "Company") were given
observation status with reference to substantial uncertainty regarding the
issuer or the pricing of its financial instruments.... ► Artikel lesen | |
| 24.04. | Diagonal Bio AB announces outcome of rights issue | ||
| 16.04. | Diagonal Bio AB publish - White paper | ||
| 08.04. | The subscription period in Diagonal Bio AB rights issue commences today | ||
| 05.04. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Diagonal Bio AB | With effect from April 08, 2024, the unit rights in Diagonal Bio AB will be
traded on First North Growth Market. Trading will continue up until and
including April 17, 2024.
Instrument: Unit rights... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
